Molecular Profile | Unknown unknown |
Therapy | PF-06647263 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | not applicable |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Advanced Solid Tumor | not applicable | PF-06647263 | Phase I | Actionable | In a Phase I trial, PF-06647263 treatment resulted in partial response in 10% (5/48) of patients with advanced solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2511)). | detail... |
---|
PubMed Id | Reference Title | Details |
---|---|---|
A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer. | Full reference... |